Over the past decade, there have been suggested molecular biomarkers to predict the risk of carcinoma in patients preoperatively diagnosed as endometrial hyperplasia, including loss of estrogen receptor (ER), PR and phosphatase and tensin homolog (PTEN) protein expression [28, 29]. The gene discussed is PTEN; the disease is carcinoma.